---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-005312"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:35:42.687571+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anika Q2 rev $39.7M (+4%); net loss ($2.8M) vs prior profit $6.5M

## Summary
- Q2 revenue $39.7M (+4% YoY); OA Pain Mgmt $25.7M (+6%), Joint Preservation $12.1M (+2%).
- Net loss ($2.8M) or ($0.20)/share vs prior net income $6.5M ($0.45); adjusted net loss ($1.6M) or ($0.12)/share.
- Adjusted EBITDA $4.4M vs $6.1M; cash $91.4M, no debt.
- X-Twist Fixation System FDA 510(k) clearance received; limited market release on schedule for 2H 2022.

## SEC filing metadata
- accession: 0001171843-22-005312
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184322005312/0001171843-22-005312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184322005312/f8k_080322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-005312
- JSON: https://secwatch.observer/filing/0001171843-22-005312.json
- Plain text: https://secwatch.observer/filing/0001171843-22-005312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.